We congratulate John Beigel and colleagues¹ in doing the first randomised-controlled, multicentre trial on adjunctive immune plasma for severe influenza, and reported clinical benefits when given before 5 days of illness, compared with neuraminidase inhibitor treatment alone. Our region's experiences with serotherapy (convalescent plasma or serum and hyperimmune intravenous immunoglobulin [IVIG]) in severe acute respiratory syndrome (SARS)-coronavirus infection, avian (A/H5N1 and A/H7N9) virus infections, and pandemic (A/H1N1_pdm09) influenza virus infection, have suggested probable benefits.

中文翻译：

---

血清流感治疗严重流感的潜力和挑战

我们祝贺John Beigel及其同事¹进行了针对严重流感的辅助免疫血浆的首个随机对照，多中心试验，并报告了与单独使用神经氨酸酶抑制剂治疗相比，在病假5天前给予的临床益处。我们地区在严重急性呼吸系统综合症（SARS）-冠状病毒感染，禽类（A / H5N1和A / H7N9）病毒感染和大流行（A / H1N1 _pdm09）的血清疗法（恢复血浆或血清和超免疫静脉免疫球蛋白[IVIG]）方面的_经验）流感病毒感染，已表明可能有好处。